Only in Titles

           Search results for: Caspase-10/a, human recombinant   

paperclip

#29045903   2017/10/18 Save this To Up

HpARI Protein Secreted by a Helminth Parasite Suppresses Interleukin-33.

Infection by helminth parasites is associated with amelioration of allergic reactivity, but mechanistic insights into this association are lacking. Products secreted by the mouse parasite Heligmosomoides polygyrus suppress type 2 (allergic) immune responses through interference in the interleukin-33 (IL-33) pathway. Here, we identified H. polygyrus Alarmin Release Inhibitor (HpARI), an IL-33-suppressive 26-kDa protein, containing three predicted complement control protein (CCP) modules. In vivo, recombinant HpARI abrogated IL-33, group 2 innate lymphoid cell (ILC2) and eosinophilic responses to Alternaria allergen administration, and diminished eosinophilic responses to Nippostrongylus brasiliensis, increasing parasite burden. HpARI bound directly to both mouse and human IL-33 (in the cytokine's activated state) and also to nuclear DNA via its N-terminal CCP module pair (CCP1/2), tethering active IL-33 within necrotic cells, preventing its release, and forestalling initiation of type 2 allergic responses. Thus, HpARI employs a novel molecular strategy to suppress type 2 immunity in both infection and allergy.

1580 related Products with: HpARI Protein Secreted by a Helminth Parasite Suppresses Interleukin-33.

Rat monoclonal anti mouse Interleukin-34 IL34 (N-t Interleukin-34 IL34 anti Glial Fibrillary Acidic Glial Fibrillary Acidic Glial Fibrillary Acidic Acyl CoA binding Protein G protein subunit alpha 1 HCV NS3 1359 1456aa antig HIV 1 intergase antigen. VZV ORF26 recombinant ant Allergens, Phospholipase

Related Pathways

  •  
  • No related Items
paperclip

#29045335   2017/10/18 Save this To Up

Angiotensin-converting enzyme 2 and renal disease.

The renin-angiotensin system (RAS) is a pivotal player in the physiology and pathophysiology of cardiovascular and renal systems. Discovery of angiotensin-converting enzyme 2 (ACE2), capable of cleaving RAS effector peptide angiotensin (Ang) II into biologically active Ang-(1-7), has increased the complexity of our knowledge of the RAS. ACE2 expression is abundant in the kidney and is thought to provide protection against injury. This review emphasizes current experimental and clinical findings that examine ACE2 in the context of kidney injury and its potential therapeutic impact for treatment of kidney disease.

1627 related Products with: Angiotensin-converting enzyme 2 and renal disease.

Human Angiotensin convert Renal disease spectrum ti Rat monoclonal anti mouse ELISA Human , Angiotensin Anti-Ace2(Angiotensin-con Anti Ace2(Angiotensin con Angiotensin Converting En Angiotensin Converting En Angiotensin Converting En Angiotensin Converting En Angiotensin Converting En Angiotensin Converting En

Related Pathways

paperclip

#29044985   2017/10/18 Save this To Up

Beneficial effect of recombinant rC1rC2 collagenases on human islet function: Efficacy of low dose enzymes on pancreas digestion and yield.

High number of human islets can be isolated using modern purified tissue dissociation enzymes, however it requires using >20 Wunsch Unit (WU)/gram of pancreas for digestion. Attempts to reduce this dose have resulted in pancreas under-digestion and poor islet recovery but improved islet function. In this study, we achieved high number of functional islets using low dose of recombinant collagenase enzyme mixture (RCEM). The collagenase dose used in these isolations is about 42% of the natural collagenase enzyme mixture (NCEM) dose commonly used to digest a 100g pancreas. Low dose RCEM was efficient in digesting entire pancreases to obtain higher yield (5,535±830 IEQ/gram and 2,582±925 IEQ/gram, P<0.05) and lesser undigested tissue (16.7±5% and 37.8±3%, P<0.05) when compared to low dose NCEM (12WU/gram). Additionally, low dose RCEM islets retained better morphology (confirmed by scanning electron microscopy), and higher in vitro basal insulin release (2391 ± 1342 μU/ml and 1778 ± 978 μU/ml; P<0.05) when compared to standard NCEM dose. Nude mouse bioassay demonstrated better islet function for low dose RCEM (AUC 24,968) over low (AUC-38,225) or standard NCEM dose (AUC-38,685), p<0.05. This is the first report indicating that islet function can be improved by using low dose rC1rC2 (RCEM). This article is protected by copyright. All rights reserved.

2020 related Products with: Beneficial effect of recombinant rC1rC2 collagenases on human islet function: Efficacy of low dose enzymes on pancreas digestion and yield.

Recombinant Human Oncosta Oncostatin M, human recom Oncostatin M, human recom RAP2C, member of RAS onco Human enzymes and protein Mouse anti human Oncostat Recombinant Human Androge Bcl-2 Oncoprotein; Clone Bcl-2 Oncoprotein; Clone c-erbB-2 Oncoprotein c-erbB-2 Oncoprotein c-erbB-3 Oncoprotein; Cl

Related Pathways

paperclip

#29044771   2017/10/18 Save this To Up

Alkaloids of Amaryllidaceae as Inhibitors of Cholinesterases (AChEs and BChEs): An Integrated Bioguided Study.

Enzymatic inhibition of acetylcholinesterase (AChE) is an essential therapeutic target for the treatment of Alzheimer's disease (AD) and AChE inhibitors are the first-line drugs for it treatment. However, butyrylcholinesterase (BChE), contributes critically to cholinergic dysfunction associated with AD. Thus, the development of novel therapeutics may involve the inhibition of both cholinesterase enzymes.

1429 related Products with: Alkaloids of Amaryllidaceae as Inhibitors of Cholinesterases (AChEs and BChEs): An Integrated Bioguided Study.

Bovine Androstenedione,AS anti CD16 monoclonal anti Astrovirus antibody, Mono Annexin V FITC Reagent Annexin V FITC Reagent100 Annexin V FITC Reagent Annexin V FITC Reagent200 Annexin V Cy3 Reagent Annexin V Cy3 Reagent1000 Annexin V Cy3 Reagent Annexin V Cy3 Reagent200 Annexin V Biotin Reagent1

Related Pathways

  •  
  • No related Items
paperclip

#29044421   2017/10/18 Save this To Up

Heterogeneous hCG and hMG commercial preparations result in different intracellular signalling but induce a similar long-term progesterone response in vitro.

Are four urinary hCG/menotropin (hMG) and one recombinant preparation characterized by different molecular features and do they mediate specific intracellular signaling and steroidogenesis?

1678 related Products with: Heterogeneous hCG and hMG commercial preparations result in different intracellular signalling but induce a similar long-term progesterone response in vitro.

Goat Anti-Human HMGB3 HMG Resorufin Oleate, Fluorog Interleukin-34 IL34 (N-t Anti AGO2 Human, Monoclon Anti AGO2 Mouse, Monoclon Anti AGO2 Human, Monoclon Anti AGO2 Mouse, Monoclon Amplite™ Intracellular Goat Anti-Human F2R PAR1, Goat Anti-Mouse APOBEC1, TGF beta induced factor 2 Cell Meter™ Intracellul

Related Pathways

paperclip

#29044175   2017/10/18 Save this To Up

A Skeletal Muscle Model of Infantile-onset Pompe Disease with Patient-specific iPS Cells.

Pompe disease is caused by an inborn defect of lysosomal acid α-glucosidase (GAA) and is characterized by lysosomal glycogen accumulation primarily in the skeletal muscle and heart. Patients with the severe type of the disease, infantile-onset Pompe disease (IOPD), show generalized muscle weakness and heart failure in early infancy. They cannot survive over two years. Enzyme replacement therapy with recombinant human GAA (rhGAA) improves the survival rate, but its effect on skeletal muscle is insufficient compared to other organs. Moreover, the patho-mechanism of skeletal muscle damage in IOPD is still unclear. Here we generated induced pluripotent stem cells (iPSCs) from patients with IOPD and differentiated them into myocytes. Differentiated myocytes showed lysosomal glycogen accumulation, which was dose-dependently rescued by rhGAA. We further demonstrated that mammalian/mechanistic target of rapamycin complex 1 (mTORC1) activity was impaired in IOPD iPSC-derived myocytes. Comprehensive metabolomic and transcriptomic analyses suggested the disturbance of mTORC1-related signaling, including deteriorated energy status and suppressed mitochondrial oxidative function. In summary, we successfully established an in vitro skeletal muscle model of IOPD using patient-specific iPSCs. Disturbed mTORC1 signaling may contribute to the pathogenesis of skeletal muscle damage in IOPD, and may be a potential therapeutic target for Pompe disease.

2715 related Products with: A Skeletal Muscle Model of Infantile-onset Pompe Disease with Patient-specific iPS Cells.

Actin, Muscle Specific; Actin, Muscle Specific; Actin, Muscle Specific; Muscle disease spectrum ( Smooth muscle and striate Anti-bodywall muscle cell Anti bodywall muscle cell Anti-bodywall muscle cell Anti bodywall muscle cell Anti-bodywall muscle cell Anti bodywall muscle cell Anti-bodywall muscle cell

Related Pathways

paperclip

#29043996   2017/10/18 Save this To Up

Clinical therapeutic strategy of recombinant human brain natriuretic peptide and dopamine in cardiorenal syndrome type 4 patients combined with hypotension.

Aim of the present study is to investigate the clinical efficacy of recombinant human brain natriuretic peptide (rhBNP) and dopamine combination treatment in patients with cardiorenal syndrome type 4 (CRS4) combined with hypotension. A total of 160 CRS4 patients admitted to our hospital from July 2010 to December 2014 were recruited, and were randomly divided into two groups, the observational group (n=80) and the control group (n=80). CRS4 patients treated with dopamine were recruited into the control group. Patients in the observational group were given rhBNP and dopamine combination treatment once every 8 h. Both groups received conventional treatments and the course of treatment was 7 days. Systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), heart rate (HR), serum creatinine (SCr), N-terminal brain natriuretic peptide precursor (Nt-proBNP), creatinine clearance (CCr), left ventricular end-diastolic diameter (LVEDd), left ventricular ejection fraction (LVEF), Stroke volume (SV), urine volume and adverse reactions before and after treatment were compared. The observational group showed significant changes in the levels of SBP, DBP and HR compared with the control group (P<0.05). The levels of SCr and Nt-proBNP decreased significantly in the observational group than those in the control group (P<0.05). The levels of CCr, LVEF, SV and urine volume increased significantly in the observational group than those in the control group (P<0.05). Patients in the observational group had mild and tolerable adverse reactions. rhBNP combined with dopamine infusion has good clinical efficacy and mild adverse effects in treatment of CRS4.

2172 related Products with: Clinical therapeutic strategy of recombinant human brain natriuretic peptide and dopamine in cardiorenal syndrome type 4 patients combined with hypotension.

Recombinant Human pro-Bra Beta Amyloid (42) ELISA K Beta Amyloid (1 40) ELISA Beta Amyloid (40) ELISA K Beta Amyloid (1 40) ELISA Recombinant Human B type Recombinant Human B type Frozen multiple human org Anti-human brain natriure Anti human brain natriure Brain Natriuretic Peptide Brain Natriuretic Peptide

Related Pathways

paperclip

#29043661   2017/10/18 Save this To Up

Development of Adenosine Deaminase-Specific IgY Antibodies: Diagnostic and Inhibitory Application.

Adenosine deaminase (ADA) is currently used as a diagnostic marker for tuberculous pleuritis. Although ADA has been suggested as a potential marker for several types of cancer, the importance of each of ADA isoforms as well as their levels and enzymatic activities in tumors need to be further investigated. Herein we developed avian immunoglobulin Y highly specific to human ADA via hens immunization with calf adenosine deaminase. The obtained antibodies were used for the development of a sensitive double-egg yolk immunoglobulin (IgY) sandwich ELISA assay with an ADA detection limit of 0.5 ng/ml and a linearity range of up to 10 ng/ml. Specific, affinity-purified IgYs were able to recognize human recombinant ADA and ADA present in human cancer cell lines. In addition, antigen-specific IgY antibodies were able to inhibit catalytic activity of calf ADA with an IC50 value of 47.48 nM. We showed that generated IgY antibodies may be useful for ADA detection, thus acting as a diagnostic agent in immunoenzymatic assays.

1889 related Products with: Development of Adenosine Deaminase-Specific IgY Antibodies: Diagnostic and Inhibitory Application.

Adenosine Deaminase antib Rabbit anti Chicken IgY a PABP1-dependent poly A-sp Adenosine A2A-R antibody Adenosine A2A-R antibody Apoptosis antibody array Cell cycle antibody array Cytokine antibody array i Master antibody array is Signal transduction antib AKT Phospho-Specific Arra AKT PKB Signaling Phospho

Related Pathways

paperclip

#29043584   2017/10/18 Save this To Up

Determination of the human cytochrome P450 monooxygenase catalyzing the enantioselective oxidation of 2,2',3,5',6-pentachlorobiphenyl (PCB 95) and 2,2',3,4,4',5',6-heptachlorobiphenyl (PCB 183).

2,2',3,5',6-Pentachlorobiphenyl (PCB 95) and 2,2',3,4,4',5',6-heptachlorobiphenyl (PCB 183) possess axial chirality and form the aS and aR enantiomers. The enantiomers of these congeners have been reported to accumulate in the human body enantioselectively via unknown mechanisms. In this study, we determined the cytochrome P450 (CYP) monooxygenase responsible for the enantioselective oxidization of PCB 95 and PCB 183, using a recombinant human CYP monooxygenase. We evaluated 13 CYP monooxygenases, namely CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2E1, CYP2J2, CYP3A4, CYP3A5, CYP4F2, and aromatase (CYP19), and revealed that CYP2A6 preferably oxidizes aS-PCB 95 enantioselectively; however, it did not oxidize PCB 183. The enantiomer composition was elevated from 0.5 (racemate) to 0.54. In addition, following incubation with CYP2A6, the enantiomer fraction (EF) of PCB 95 demonstrated a time-dependent increase.

1948 related Products with: Determination of the human cytochrome P450 monooxygenase catalyzing the enantioselective oxidation of 2,2',3,5',6-pentachlorobiphenyl (PCB 95) and 2,2',3,4,4',5',6-heptachlorobiphenyl (PCB 183).

YKL-39 antibody Source Ra PCBP2 antibody Source Rab TCP-1 theta antibody Sour Cytochrome P450 4A11 anti Recombinant Human PKC the Recombinant Human PKC the Recombinant Human PKC the Human Cytochrome P450 2D6 Goat Anti-Human PCBP4, (C Cytochrome P450 2C9 Cytochrome P450 3A4 BACTERIOLOGY BACTEROIDES

Related Pathways

  •  
  • No related Items
paperclip

#29042604   2017/10/18 Save this To Up

Placenta-specific1 (PLAC1) is a potential target for antibody-drug conjugate-based prostate cancer immunotherapy.

Our recent findings strongly support the idea of PLAC1 being as a potential immunotherapeutic target in prostate cancer (PCa). Here, we have generated and evaluated an anti-placenta-specific1 (PLAC1)-based antibody drug conjugate (ADC) for targeted immunotherapy of PCa. Prostate cancer cells express considerable levels of PLAC1. The Anti-PLAC1 clone, 2H12C12, showed high reactivity with recombinant PLAC1 and selectivity recognized PLAC1 in prostate cancer cells but not in LS180 cells, the negative control. PLAC1 binding induced rapid internalization of the antibody within a few minutes which reached to about 50% after 15 min and almost completed within an hour. After SN38 conjugation to antibody, a drug-antibody ratio (DAR) of about 5.5 was achieved without apparent negative effect on antibody affinity to cell surface antigen. The ADC retained intrinsic antibody activity and showed enhanced and selective cytotoxicity with an IC50 of 62 nM which was about 15-fold lower compared to free drug. Anti-PLAC1-ADC induced apoptosis in human primary prostate cancer cells and prostate cell lines. No apparent cytotoxic effect was observed in in vivo animal safety experiments. Our newly developed anti-PLAC1-based ADCs might pave the way for a reliable, efficient, and novel immunotherapeutic modality for patients with PCa.

2262 related Products with: Placenta-specific1 (PLAC1) is a potential target for antibody-drug conjugate-based prostate cancer immunotherapy.

MOUSE ANTI BOVINE ROTAVIR MOUSE ANTI BORRELIA BURGD RABBIT ANTI GSK3 BETA (pS MOUSE ANTI CANINE DISTEMP MOUSE ANTI HUMAN CD15, Pr MOUSE ANTI HUMAN CD19 RPE MOUSE ANTI HUMAN CD15, Pr MOUSE ANTI APAAP COMPLEX, serologically defined col NATIVE HUMAN PROLACTIN, P 10x ELISA WASH BUFFER, Pr 10X PHOSPHATE BUFFERED SA

Related Pathways